Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

QURE

uniQure N.V.

Jun 18 • 04:00PM ET

4.57

Dollar change -0.12
Percentage change -2.56	%

Healthcare • Biotechnology • Netherlands • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF IBB SCHA VHT PRFZ ITOT IDNA GNOM AVSC SCHB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.20	Insider Own	2.05%	Shs Outstand	47.83M	Perf Week	-12.62%
Market Cap	221.87M	Forward P/E	-	EPS next Y	-3.77	Insider Trans	-7.19%	Shs Float	47.55M	Perf Month	-8.78%
Income	-296.87M	PEG	-	EPS next Q	-1.23	Inst Own	67.07%	Short Float	6.24%	Perf Quarter	-10.92%
Sales	19.00M	P/S	11.68	EPS this Y	31.20%	Inst Trans	-4.79%	Short Ratio	4.88	Perf Half Y	-44.74%
Book/sh	3.03	P/B	1.51	EPS next Y	15.21%	ROA	-42.38%	Short Interest	2.97M	Perf Year	-76.50%
Cash/sh	11.45	P/C	0.40	EPS next 5Y	-	ROE	-106.11%	52W Range	4.25 - 19.63	Perf YTD	-32.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.59%	ROI	-43.58%	52W High	-76.72%	Beta	0.97
Dividend TTM	-	Quick Ratio	9.27	Sales past 5Y	302.35%	Gross Margin	-70.61%	52W Low	7.53%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	9.39	EPS Y/Y TTM	-85.41%	Oper. Margin	-1332.12%	RSI (14)	36.44	Volatility	4.75% 5.39%
Employees	480	Debt/Eq	3.70	Sales Y/Y TTM	-82.73%	Profit Margin	-1562.22%	Recom	1.62	Target Price	18.36
Option/Short	Yes / Yes	LT Debt/Eq	3.64	EPS Q/Q	16.70%	Payout	-	Rel Volume	1.00	Prev Close	4.69
Sales Surprise	35.12%	EPS Surprise	-6.32%	Sales Q/Q	59.34%	Earnings	May 07 BMO	Avg Volume	608.62K	Price	4.57
SMA20	-9.28%	SMA50	-6.64%	SMA200	-23.53%	Trades		Volume	609,003	Change	-2.56%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-29-24	Downgrade	Goldman	Buy → Neutral	$8
Dec-19-23	Downgrade	Mizuho	Buy → Neutral	$52 → $10
Mar-17-22	Upgrade	UBS	Neutral → Buy	$40
Jun-15-21	Initiated	BTIG Research	Buy	$46
May-21-21	Initiated	UBS	Neutral	$40
Apr-26-21	Resumed	Credit Suisse	Outperform	$78
Apr-01-21	Upgrade	Mizuho	Neutral → Buy	$52
Jan-07-21	Upgrade	Guggenheim	Neutral → Buy	$62
Nov-24-20	Initiated	H.C. Wainwright	Buy	$80
Nov-11-20	Initiated	Berenberg	Buy
Nov-09-20	Initiated	Jefferies	Buy	$55
Nov-04-20	Initiated	Cantor Fitzgerald	Overweight	$65
Oct-23-20	Initiated	RBC Capital Mkts	Outperform	$61
Aug-25-20	Initiated	Raymond James	Strong Buy	$75
Jul-31-20	Upgrade	Robert W. Baird	Neutral → Outperform	$57
Jun-25-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$56
Jun-25-20	Downgrade	Robert W. Baird	Outperform → Neutral	$58
Jun-25-20	Downgrade	Mizuho	Buy → Neutral	$90 → $61
Dec-03-19	Initiated	Goldman	Buy
Dec-03-19	Initiated	Cowen	Outperform

Show Previous Ratings

Jun-03-24 07:05AM	uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntingtons Disease (GlobeNewswire) +7.68%
May-07-24 01:53PM	QURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:24AM	UniQure: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Feb-29-24 09:06AM	uniQure NV CEO Matthew Kapusta Sells 27,904 Shares (GuruFocus.com) -14.05%
Feb-28-24 08:35AM	uniQure NV (QURE) Reports 2023 Financial Results Amid Strategic Reorganization (GuruFocus.com)
08:20AM	UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:05AM	uniQure Announces 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey) +5.80%
Dec-19-23 07:15AM	Investors still arent sold on UniQures gene therapy for Huntingtons (BioPharma Dive) -16.79%
07:05AM	uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease (GlobeNewswire)
Dec-11-23 07:30PM	CSL Behring's HEMGENIX (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B (PR Newswire)
Dec-10-23 11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Dec-08-23 07:05AM	uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:08AM	5 Best Falling Stocks To Buy Now (Insider Monkey)
Nov-29-23 07:05AM	uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease (GlobeNewswire)
Nov-14-23 10:31PM	3 Micro-Cap Stocks That Could Be Moonshots (InvestorPlace) +10.33%
Nov-08-23 09:55AM	Wall Street Analysts Believe uniQure (QURE) Could Rally 405.37%: Here's is How to Trade (Zacks) -5.45%
Nov-07-23 08:25AM	UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +12.68%
08:12AM	uniQure NV (QURE) Reports Q3 2023 Earnings: Net Loss Widens, Cash Position Strengthens (GuruFocus.com)
07:21AM	UniQure: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Oct-27-23 10:00AM	CSL and uniQure Win 2023 Prix Galien USA Award (PR Newswire)
Oct-26-23 02:14PM	Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B (PR Newswire)
10:02AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-25-23 10:02AM	UniQure (QURE) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -5.65%
Oct-24-23 07:05AM	uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting (GlobeNewswire)
Oct-12-23 08:24AM	Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback (Zacks) -8.68%
Oct-06-23 11:31AM	uniQure (QURE) Up on Restructuring Plans, Workforce Reduction (Zacks)
Oct-05-23 01:49PM	Why Shares of uniQure Are Up Thursday (Motley Fool) +11.61%
08:15AM	UPDATE 1-Gene therapy maker UniQure to cut about 20% of workforce (Reuters)
07:19AM	UniQure to lay off about 20% of workforce (Reuters)
07:05AM	uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs (GlobeNewswire)
Oct-02-23 07:05AM	uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.90%
Sep-05-23 01:10PM	Why Shares of uniQure Are Dropping Tuesday (Motley Fool) -9.86%
07:05AM	uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy (GlobeNewswire)
Sep-01-23 06:51PM	Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey)
Aug-26-23 03:51PM	3 Tantalizing Stocks to Buy for Under $10 (InvestorPlace)
Aug-06-23 08:05AM	Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be (Simply Wall St.)
Aug-01-23 09:05AM	UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:54AM	UniQure: Q2 Earnings Snapshot (AP Finance)
07:05AM	uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Jul-27-23 08:35PM	Down More Than 40%: Analysts Say Buy These 2 Beaten-Down Stocks Before They Rebound (TipRanks)
Jun-28-23 09:20AM	FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing (Zacks)
06:02AM	Party Time: Brokers Just Made Major Increases To Their uniQure N.V. (NASDAQ:QURE) Earnings Forecasts (Simply Wall St.)
Jun-26-23 07:11AM	uniQure Announces Leadership Addition to Support Advancement of Clinical Programs (GlobeNewswire)
Jun-22-23 03:03PM	Why uniQure Stock Cratered This Week (Motley Fool)
10:17AM	uniQure (QURE) Falls on Mixed Huntington's Disease Study Results (Zacks)
Jun-21-23 08:00PM	QURE: Lowering target price to $13.00 (Argus Research) -40.23%
04:08PM	Uniqure Crashes To Six-Year Low On Muddy Results For Huntington's Gene Therapy (Investor's Business Daily)
11:46AM	Why uniQure Stock Is Crashing Today (Motley Fool)
07:05AM	uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntingtons Disease (GlobeNewswire)
Jun-20-23 07:05AM	uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy (GlobeNewswire)
07:00AM	CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B (PR Newswire)
Jun-16-23 07:05AM	uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-23 07:53AM	UPDATE 1-UniQure to sell royalty interest in blood disorder therapy for up to $400 mln (Reuters)
07:05AM	uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million (GlobeNewswire)
May-14-23 08:16AM	The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically (Simply Wall St.)
May-09-23 08:25AM	UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:21AM	UniQure: Q1 Earnings Snapshot (AP Finance)
07:05AM	uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-02-23 04:40PM	uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire)
07:05AM	uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-26-23 08:00PM	QURE: What does Argus have to say about QURE? (Argus Research)
Apr-17-23 10:31AM	uniQure N.V.'s (NASDAQ:QURE) Price Is Right But Growth Is Lacking (Simply Wall St.)
Mar-13-23 07:05AM	uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-10-23 09:07AM	Are Options Traders Betting on a Big Move in UniQure (QURE) Stock? (Zacks) -5.89%
Mar-02-23 07:05AM	uniQure to Participate in Multiple Upcoming Industry Conferences in March (GlobeNewswire)
Feb-28-23 04:19PM	uniQure Stock Trying To Close In On Key Technical Measure (Investor's Business Daily)
Feb-27-23 08:25AM	UniQure (QURE) Tops Q4 Earnings and Revenue Estimates (Zacks) +5.21%
07:05AM	uniQure Announces 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-23-23 08:05AM	uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb) (GlobeNewswire)
08:00AM	CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb) (PR Newswire)
05:34AM	The Petri Dish: Blindness drug approved; Moderna strikes gene-editing deal (American City Business Journals)
Feb-21-23 07:05AM	uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B (GlobeNewswire)
Jan-31-23 07:05AM	uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1 (GlobeNewswire)
Jan-06-23 05:39AM	3 Growth Stocks That Could Rocket Higher in 2023 (Motley Fool)
Dec-20-22 07:05AM	uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-16-22 07:15AM	uniQure announces positive CHMP opinion for etranacogene dezaparvovec gene therapy for adults with hemophilia B (GlobeNewswire)
Dec-10-22 10:00AM	CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment (PR Newswire)
Nov-29-22 11:00AM	uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event (GlobeNewswire) -5.97%
Nov-23-22 05:30PM	Why Shares of uniQure Rose 14.61% on Wednesday (Motley Fool) +14.61%
04:14PM	The FDA Just Approved Its Most Expensive Drug Ever Sending UniQure Stock On A Warpath (Investor's Business Daily)
01:19PM	For Lexington's UniQure, hemophilia gene therapy approval is a comeback story (American City Business Journals)
12:39PM	uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy (Zacks)
08:12AM	FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults (Benzinga)
Nov-22-22 04:40PM	uniQure announces FDA approval of first gene therapy for adults with hemophilia B (GlobeNewswire) +7.08%
03:59PM	U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B (PR Newswire)
Nov-17-22 07:05AM	uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022 (GlobeNewswire)
Nov-10-22 09:55AM	uniQure (NASDAQ:QURE shareholders incur further losses as stock declines 8.3% this week, taking three-year losses to 66% (Simply Wall St.) +10.74%
Nov-02-22 08:35AM	UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +7.27%
07:05AM	uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-17-22 10:00AM	Analysts Estimate uniQure (QURE) to Report a Decline in Earnings: What to Look Out for (Zacks) +5.16%
Oct-11-22 07:05AM	uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT) (GlobeNewswire)
Oct-03-22 07:05AM	uniQure to Participate in Upcoming Industry Conferences in October (GlobeNewswire)
Sep-06-22 07:05AM	uniQure to Participate in Upcoming Industry Conferences in September (GlobeNewswire) -5.61%
Aug-14-22 08:23AM	These Analysts Just Made A Neat Downgrade To Their uniQure N.V. (NASDAQ:QURE) EPS Forecasts (Simply Wall St.)

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Potts Jeannette	Chief Legal Officer	Jun 13 '24	Sale	4.98	4,781	23,809	91,819	Jun 17 07:46 PM
Gut Robert	Director	Jun 13 '24	Sale	5.12	3,504	17,940	44,165	Jun 17 07:19 PM
Kaye Jack	Director	Jun 13 '24	Sale	5.16	2,218	11,445	6,501	Jun 17 07:14 PM
Balachandran Madhavan	Director	Jun 13 '24	Sale	5.12	2,231	11,423	23,759	Jun 17 07:30 PM
Springhorn Jeremy P.	Director	Jun 13 '24	Sale	5.12	2,231	11,423	23,756	Jun 17 07:40 PM
POST LEONARD E	Director	Jun 13 '24	Sale	5.14	2,222	11,421	15,999	Jun 18 06:11 PM
Jacques Rachelle Suzanne	Director	Jun 13 '24	Sale	5.14	2,221	11,416	14,408	Jun 17 06:42 PM
Meek David D.	Director	Jun 13 '24	Sale	5.12	2,229	11,412	20,252	Jun 17 07:35 PM
Soteropoulos Paula	Director	Jun 13 '24	Sale	5.14	2,220	11,411	20,203	Jun 17 07:24 PM
Kapusta Matthew C	CEO, Managing Director	Feb 26 '24	Sale	6.35	27,904	177,190	440,839	Feb 28 04:17 PM
KLEMT CHRISTIAN	Chief Financial Officer	Feb 26 '24	Sale	6.38	15,906	101,480	116,948	Feb 28 04:21 PM
CALOZ PIERRE	Chief Operating Officer	Feb 26 '24	Sale	6.47	9,455	61,174	85,643	Feb 28 04:33 PM
Dolmetsch Ricardo	President, R&D	Sep 18 '23	Sale	7.46	5,841	43,574	163,404	Sep 20 04:45 PM
CALOZ PIERRE	Chief Operating Officer	Jul 10 '23	Sale	11.36	15,117	171,729	95,098	Jul 12 04:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QURE

uniQure N.V.

Upgrade your FINVIZ experience